Navigation Links
Viralytics Full Year Financial Results
Date:9/3/2013

ustralia and the UK)

  • Broad anti-cancer activity of CAVATAK™ demonstrated in preclinical setting.
  • Synergistic effect from the combination of CAVATAK™ and Docetaxel.  Potential combination therapy.
  • Combination with either radiation or chemotherapy resulted in more potent anticancer activity in bladder cancer cell lines than radiation or chemotherapy alone.
  • Potent anti-cancer activity in chronic lymphocytic leukaemia (CLL) cell lines.
  • "The 2013 financial year has been one of outstanding progress at Viralytics, which leaves us well positioned to further develop the business in the coming year," said Dr. Malcolm McColl, Chief Executive Officer of Viralytics. "We have achieved key milestones in our Phase 2 CALM study, with interim results demonstrating promising anti-cancer activity. We also had a number of excellent outcomes in our Phase 1 and preclinical programs, demonstrating the broad anti-cancer activity of CAVATAK™.  Our focus is to maintain momentum in clinical development and translate this progress into valuable commercial outcomes."

    About Viralytics Ltd:
    Viralytics is developing oncolytic virotherapy treatments for a range of cancers.  Viralytics' lead product, CAVATAK™, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21).  CVA21 binds to specific "receptor" proteins highly expressed on multiple cancer types including, but not limited to melanoma, prostate, lung, breast and bladder cancers; and multiple myeloma.  Intratumourally administered CAVATAK™ is currently being studied in a Phase 2 clinical trial in the treatment of Late stage Melanoma (the CALM study) at multiple cancer clinics in the US.  Viralytics also plans to commence a Phase 1/2 study of CAVATAK™ delivered intravenously in patients with melanoma, prostate, lung or metastatic bladder cancers prior to the en
    '/>"/>

    SOURCE Viralytics Ltd.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2013 Financial Results
    2. International Isotopes Inc. Announces Second Quarter and Six Months 2013 Financial Results
    3. ULURU Inc. Reports Second Quarter 2013 Financial Results
    4. Tengion Provides Business Update and Reports Second Quarter 2013 Financial Results
    5. EntreMed Reports Second Quarter 2013 Financial Results
    6. Savient Pharmaceuticals Reports Second Quarter 2013 Financial Results
    7. Sinovac Reports Unaudited Second Quarter 2013 Financial Results
    8. Vasomedical Announces Financial Results for the Second Quarter of 2013
    9. Nephros Reports Second Quarter 2013 Financial Results
    10. Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights
    11. Dynasil Corporation of America Reports Third Quarter Fiscal 2013 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2015)... MONROVIA, Calif. , July 31, 2015  Xencor, ... developing engineered monoclonal antibodies for the treatment of autoimmune ... the appointment of Yujiro S. Hata to ... of experience in business and corporate development is a ... , Ph.D., president and chief executive officer of Xencor. ...
    (Date:7/30/2015)... -- Mettler-Toledo International Inc. (NYSE: MTD ) today ... the highlights: , Sales in local currency ... year. Reported sales decreased 4% as currency reduced sales ... earnings per diluted share as reported (EPS) were $2.73, ... was $2.80 , an increase of 9% over ...
    (Date:7/30/2015)... 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... of the t:slim® and t:flex™ Insulin Pumps, today ... Agreements with Dexcom, Inc. to allow the integration ... Dexcom G5 and G6 continuous glucose monitoring ("CGM") ... platform with Dexcom,s future CGM systems is an ...
    Breaking Medicine Technology:Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
    ... WATERTOWN, Mass., Nov. 16 "Temporal artery thermometry is an ... four years of age," according to a recent study published ... investigated the sensitivity and specificity of scanning the forehead area ... temperatures in children 1-4 years old. , "This independent research ...
    ... , FARMINGDALE, N.Y., Nov. 16 Misonix, Inc. (Nasdaq: ... device technology, which in Europe is used for the ablation ... reported the financial results for the first fiscal quarter 2010 ... and Chief Executive Officer, and Richard Zaremba, Senior VP and ...
    Cached Medicine Technology:Exergen TemporalScanner Effective in Detecting Fevers in Children Aged 1-4 Years, Study Finds 2Misonix Reports First Quarter Fiscal 2010 Financial Results 2Misonix Reports First Quarter Fiscal 2010 Financial Results 3Misonix Reports First Quarter Fiscal 2010 Financial Results 4Misonix Reports First Quarter Fiscal 2010 Financial Results 5Misonix Reports First Quarter Fiscal 2010 Financial Results 6Misonix Reports First Quarter Fiscal 2010 Financial Results 7Misonix Reports First Quarter Fiscal 2010 Financial Results 8Misonix Reports First Quarter Fiscal 2010 Financial Results 9
    (Date:7/31/2015)... ... July 31, 2015 , ... ... to know in predictive health analytics , Jvion continues to disrupt the ... creates predictive software that targets patient and population level illness to drive prevention ...
    (Date:7/31/2015)... ... 2015 , ... There’s no better way to enjoy the summer weather than ... the next meal, making July the most appropriate to be National Hot Dog Month. ... , Make the next cookout different than the ones in the past. Celebrate National ...
    (Date:7/31/2015)... ... 2015 , ... M3 USA MDLinx.com, source of the Smartest Doc Board Exam ... , The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out an already robust ... the exam easy and painless. MDLinx offers thousands of board-exam style questions and ...
    (Date:7/31/2015)... ... July 31, 2015 , ... Well-known for its unique ... wedding cakes with custom designs, making life just a little bit sweeter ... wedding cakes for each customer who orders one. , The bakery provides a full ...
    (Date:7/31/2015)... ... July 31, 2015 , ... The ... to patients and family members, medical professionals, and researchers, covering a variety of ... conference is a collaborative effort between the Mesothelioma Applied Research Foundation and Memorial ...
    Breaking Medicine News(10 mins):Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3
    ... researchers, physicians, technologists and medical experts from across ... to explore topics in nuclear medicine, molecular imaging, ... Mid-Winter Meetings. , Four meetings were held ... Educational Symposium of the American College of Nuclear ...
    ... NEW YORK , Feb. 9 As part ... development of life-transforming treatments and a cure for Parkinson,s disease, ... in total funding for seven research projects aiming to push ... therapeutic development. , While new genetic and cellular targets ...
    ... Feb. 9 Chiquita Brands International, Inc. (NYSE: ... Fresh Produce Association Foundation,s " A Salad Bar in Every ... health commitment by Chiquita and its Fresh Express subsidiary will ... across America.  Chiquita is the first produce company to commit ...
    ... clinical data for nearly 800 patients with non-small cell lung ... with age and sex specific patterns of increased or decreased ... issue of JAMA . The five-year overall survival ... remains the leading cause of cancer-related death in the United ...
    ... People with cystic fibrosis, an inherited disease that clogs ... defy treatment. While the life expectancy for children with ... many lives are still shortened in young adulthood by ... are often caused by common, environmental microbes that mutate ...
    ... First Lady Michelle ... number of chronic diseases including diabetes, heart disease, osteoarthritis, and sleep apnea. ... Washington, DC (Vocus) February 9, ... a risk factor for a number of chronic diseases including diabetes, heart disease, osteoarthritis, and ...
    Cached Medicine News:Health News:SNM's Conjoint Mid-Winter Meetings continue to advance molecular imaging 2Health News:SNM's Conjoint Mid-Winter Meetings continue to advance molecular imaging 3Health News:Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinson's Drug Development 2Health News:Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinson's Drug Development 3Health News:Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinson's Drug Development 4Health News:Chiquita Announces Support for School Salad Bar Campaign 2Health News:Chiquita Announces Support for School Salad Bar Campaign 3Health News:Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer 2Health News:Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer 3Health News:Adapting to clogged airways makes common pathogen resist powerful drugs 2Health News:Adapting to clogged airways makes common pathogen resist powerful drugs 3Health News:National Wildlife Federation Says Outdoor Time for Kids Can Help First Lady Achieve Her “Let's Move” Goal 2Health News:National Wildlife Federation Says Outdoor Time for Kids Can Help First Lady Achieve Her “Let's Move” Goal 3
    BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology....
    Inquire...
    The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of...
    Inquire...
    Medicine Products: